{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', '2', 'SYNOPSIS', 'Protocol Title: A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter', 'Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects with Active Thyroid Eye Disease (OPTIC)', 'Protocol Number: HZNP-TEP-301', 'Phase: 3', 'Protocol Version: 4.0', 'Test Drug: Teprotumumab (HZN-001)', 'Indication: Active Thyroid Eye Disease (TED)', 'Number and Country of Study Sites: Up to 16 study centers in the United States and Europe.', 'Objectives:', 'The overall objective is to investigate the efficacy, tolerability, and safety of teprotumumab (HZN-001, a fully', 'human monoclonal antibody [mAb] inhibitor of the insulin-like growth factor-1 receptor [IGF-1R])', 'administered once every 3 weeks (q3W) for 24 weeks, in comparison to placebo, in the treatment of subjects', 'with moderate-to-severe active TED.', 'Primary Objective', 'The primary objective is to evaluate the effect of teprotumumab versus placebo on the proptosis responder rate', '(i.e., the percentage of subjects with a > 2 mm reduction from Baseline in the study eye without deterioration', '[>', '2 mm increase] of proptosis in the fellow eye) at Week 24.', 'Secondary Objectives (analyzed hierarchically)', '1. Evaluate the effect of teprotumumab versus placebo on the overall responder rate (percentage of subjects', 'with > 2-point reduction in Clinical Activity Score [CAS] AND > 2 mm reduction in proptosis from', 'Baseline, provided there is no corresponding deterioration [ 2-point/mm increase] in CAS or proptosis', 'in', 'the fellow eye) at Week 24.', '2. Evaluate the effect of teprotumumab versus placebo on the percentage of subjects with a CAS value of', '0 or 1 at Week 24 in the study eye.', '3. Evaluate the effect of teprotumumab versus placebo on the mean change from Baseline to Week 24 in', 'proptosis measurement in the study eye.', '4. Evaluate the effect of teprotumumab versus placebo on the diplopia responder rate (i.e., the percentage of', 'subjects with baseline diplopia > 0 in study eye who have a reduction of > 1 grade with no corresponding', 'deterioration 1> 1 grade worsening] in the fellow eye) at Week 24.', '5.', 'Evaluate the effect of teprotumumab versus placebo on the mean change from Baseline to Week 24 in the', \"Graves' Ophthalmopathy Quality of Life (GO-QoL) questionnaire overall score.\", 'Exploratory Objectives', '1. Evaluate the effect of teprotumumab versus placebo on the Clinical Measures of Severity individual', 'response status frequencies and percentage of responders for each component of clinical severity from', 'Baseline to Week 24.', '2. Evaluate the effect of teprotumumab versus placebo on the mean change from Baseline to Week 24 in the', 'CAS.', '3. Evaluate the effect of teprotumumab versus placebo on the overall responder rate at Week 24 stratified by', 'the level of response (high responders, responders, low responders, and non-responders; see', 'Section 9.6.4.3.1 for definitions).', '4. Evaluate pharmacokinetic (PK) parameters of teprotumumab to estimate exposure and understand', 'PK-pharmacodynamic (PD) relationships.', '5.', 'Evaluate the effect of teprotumumab versus placebo on the mean change from Baseline to Week 24 in the', 'GO-QoL questionnaire visual functioning (VF) and appearance (A) subscale scores.', '6. Evaluate the effect of teprotumumab on the mean change from Baseline to Week 24 in blood and serum', 'biomarkers.', '7. Evaluate the effect of teprotumumab versus placebo on the mean change from Baseline to Week 24 on the', 'motility component of the Clinical Measures of Severity.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 22 of 117']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-301', 'Version 4.0, incorporating Amendment 3', 'Study Design:', 'This is a randomized, double-masked, placebo-controlled, parallel-group, multicenter study. Subjects will be', 'screened for the study within 2 to 6 weeks prior to the Baseline (Day 1) Visit. Approximately 76 subjects', '(38/group) who meet the study eligibility criteria will be randomized on Day 1 in a 1:1 ratio (stratified by', 'tobacco use status) to receive 8 infusions of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for the', 'remaining 7 infusions) or placebo q3W. All subjects will enter a 24-week double-masked Treatment Period,', 'during which study drug will be infused on Day 1 (Baseline), and Weeks 3, 6, 9, 12, 15, 18, and 21 (with a final', 'visit at Week 24). All study drug dosing will be performed at the clinic under the supervision of clinic staff, and', 'at any scheduled infusion, the infusion rate may be reduced or the dose may be interrupted or held based on', 'decreased tolerability (see Section 9.4.6.3.2 for details). On each dosing day, scheduled assessments (except for', 'adverse event [AE] and concomitant medication use monitoring, which will be monitored throughout the clinic', 'visit) will be completed prior to study drug dosing. After each of the first 2 infusions, subjects will be contacted', 'by phone/email the following day and will return to the clinic 1 week after the infusion (Weeks 1 and 4) for', 'safety and tolerability assessments; additional phone/email contacts and clinic visits may also be conducted for', 'any subject experiencing an infusion-associated event.', 'At the end of the double-masked Treatment Period (Week 24), subjects who are proptosis non-responders (study', 'eye has < 2 mm decrease in proptosis) will be eligible to enter an open-label extension study (HZNP-TEP-302)', 'in which subjects may receive 8 infusions of teprotumumab (10 mg/kg for the first infusion and 20 mg/kg for', 'the remaining 7 infusions) in an open-label fashion.', 'At Week 24, proptosis responders, as well as non-responders who choose not to enroll in the open-label', 'extension study (HZNP-TEP-302), will enter a 48-week Follow-Up Period, during which study drug will not be', 'administered and clinic visits are scheduled for Weeks 28, 36, 48, 60, and 72 (Months 7, 9, 12, 15, and 18).', 'Subjects who are considered responders at Week 24 but who meet criteria for re-treatment due to relapse during', 'the Follow-Up Period may enroll in the open-label extension study, HZNP-TEP-302 (see Section 9.3.4).', 'Subjects who prematurely discontinue study drug dosing prior to Week 21 of the Treatment Period will return to', 'the clinic and undergo the scheduled Week 24 assessments and will be encouraged to participate in the Follow-', 'Up Period unless they initiated another intervention due to lack of efficacy. Subjects who enter the Follow-Up', 'Period but prematurely discontinue study participation prior to 48 weeks following the double-masked', 'Treatment Period will return for a final visit and undergo the scheduled Week 72 assessments prior to study', 'discharge.', 'Subjects who complete the Week 72 Visit will be contacted 6 and 12 months later via phone or email by', 'research staff to enquire if any treatment for TED has been received since last study contact. If yes, subject will', 'be questioned regarding type of treatment and outcome/response.', 'An overview of the study design is presented in the schematic below, and details of study activities are provided', 'in Section 2.1, Schedule of Assessments.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 23 of 117']\n\n###\n\n", "completion": "END"}